MediPharm Labs Corp.
Other OTCRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- MediPharm Labs Corp. MediPharm Labs Corp. (TSX: LABS; OTCQX: MEDIF) operates as a pharmaceutical-grade cannabis company specializing in the production and distribution of precision-based cannabinoids, including cannabis extracts, concentrates, isolates, and derivative products such as oils, tinctures, soft gels, soft chews, vape cartridges, metered dose inhalers, and dissolving drops; the company provides good manufacturing practice (GMP) flower sourcing, packaging, white-label production, and distribution services through its wholesale and branded platforms to medical and consumer markets. Founded in 2015 and headquartered at 151 John Street in Barrie, Ontario, Canada, MediPharm Labs maintains operations in Canada, Australia (Wonthaggi, Victoria), Germany, Brazil, and other international markets, with a primary focus on regulated medical cannabis segments including cosmetics, food and beverage, nutraceuticals, and over-the-counter or prescribed medications; its branded portfolio features specific formulations like CBD25, CBD50, CBD100, THC30, CBN1:2, CBG:CBD 1:2, and advanced inhalers such as THC and CBN variants, all produced using full-spectrum cannabis extracts in pharmaceutical-grade amber glass packaging with MCT or olive oil carriers for precise dosing. The company supports clinical trials and academic partnerships with institutions like McMaster University and Loyalist College for cannabis-based therapies research. In recent developments, MediPharm Labs enters a landmark commercial agreement with Laboratorio Teuto in Brazil in January 2025 to supply full-spectrum GMP sublingual oral solutions for the $198 million medical cannabis market serving over 670,000 patients; it launches the CBN THC Metered Dose Inhaler and expands its CBN oil portfolio with plans for additional CBD and CBG inhaler options, while beginning production of its first international order for novel cannabis metered dose products in the EU in May 2025; earlier, in 2023, MediPharm acquired VIVO Cannabis Inc. to enhance medical patient access via Canna Farms e-commerce in Canada, Beacon Medical in Australia and Germany, and Harvest Medical Clinics, followed by the sale of its Hope, BC facility and progression toward closing the Canna Farms facility sale to Rubicon Organics; Q3 2025 reports record revenue of $11.4 million, up 17% year-over-year, with 83% growth in international medical cannabis sales.
Company News
MediPharm Labs Corp. (LABS:CA) Q2 2026 Earnings Call Transcript
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
MediPharm Labs Sets Date to Report Second Quarter 2026 Financial Results
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer's Disease and Dementia
MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders
MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders
MediPharm Labs Reminds Shareholders of Upcoming Annual and Special Meeting
MediPharm Labs Corp. (LABS:CA) Q1 2026 Earnings Call Transcript
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
MediPharm Labs Corp. (LABS:CA) Q4 2025 Earnings Call Transcript
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
MediPharm Labs to Enter New Market with Costa Rica Supply Agreement
Historic U.S. Cannabis Rescheduling Unlocks Potential Growth Opportunities for MediPharm Labs, Backed by the Company's Suite of Licenses and Proven U.S. Clinical Trial Supply Experience
MediPharm Labs Announces Board of Directors Changes: Shelley Potts Steps Down, Michael Bumby Returns
MediPharm Labs Completes First Shipment to France